PRESS RELEASE
Thursday, September 13, 2012

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India
BSE: 532531
NSE: STAR

Strides Arcolab Announces US FDA Approval of
Its Polish Sterile Injectable Facility

- All 8 Global Sterile Sites Now Approved by USFDA and EU for cGMP

September 13, 2012, Bangalore: Agila Specialties (Agila), injectables unit of Strides Arcolab Limited (Strides) today announced that it has received US FDA approval for its ‘Polish Sterile facility’.

This state-of-the-art facility located in Warsaw, Poland, manufactures vials, ampoules, pre-filled syringes and lyophilized injections.

With this approval all eight global sterile injectable sites of Agila are now approved by the US FDA and EU authorities and places Agila amongst the largest global capacities for sterile injectables.

Shipments from the Polish facility will commence within Q4’ 2012 and will run in full capacity by Q1’ 2013, as product transfers have already commenced.

Commenting on the event, Venkat Iyer, CEO, Agila Specialties, said, “This approval for our Polish sterile facility offers significant flexibility to our manufacturing which is currently experiencing strong demand on a worldwide basis”.

About Agila Specialties

Agila, Specialties business of Strides Arcolab is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 9 world-class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila’s marketing network covers 70 countries and it has partnerships with some of the world’s leading pharmaceutical companies for both developed and emerging markets.
About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company’s website at www.stridesarco.com.

For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>PR Consultancy</th>
</tr>
</thead>
</table>
| Mr. V.S. Iyer, CEO - Agila  
+91 80 6784 0111  
Mr. Ajay Singh : +91 80 6784 0813  
Mr. Kannan N : +91 98450 54745  (Investors)  | Corporate Voice | Weber Shandwick  
Mahesh Nair,  
+91 9880376648  
maheshn@corvoshandwick.co.in  
Kaveri Mandanna,  
+91 90089 59697  
kaveri@corvoshandwick.co.in |